PV Bulletin

CDA-AMC Post-Market Drug Evaluation (PMDE) Program Procedural Update

Canada's Drug Agency updated PMDE program procedures affecting post-market drug safety evaluations and signal assessments.

Primary source: Canada's Drug Agency (CDA-AMC)

PV Impact Brief

MonitoringConfidence: high

What changed

CDA-AMC updated PMDE Program procedures to refine evaluation initiation processes and incorporate real-world data for safety reviews and regulatory decisions.

Why it matters

The update alters how MAHs interact with Canadian authorities during post-market safety evaluations and signal assessments, potentially impacting submission timelines and data requirements.

Action needed

Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Signal ManagementCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Quarterly

Policy change details

Document type
SOP
Policy status
revised
Publication date
2026-06-05
Policy change
Canada's Drug Agency (CDA-AMC) has updated its Post-Market Drug Evaluation (PMDE) Program procedures, which provide national coordination for evaluating drug safety and effectiveness after products enter the market.

Key changes

Refines processes for the initiation of evaluations and the use of real-world data to inform safety reviews and regulatory decisions in Canada.

Affected workflows

Signal ManagementCountry Compliance

Responsible groups

Pharmacovigilance OperationsRegulatory AffairsMedical Affairs

PV impact

Affects the interaction between MAHs and Canadian health authorities during post-market safety evaluations and signal assessments.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.

Canada's Drug Agency (CDA-AMC) updated its Post-Market Drug Evaluation (PMDE) Program, refining processes for initiating evaluations and using real-world data. This affects marketing authorization holders' interaction with Canadian health authorities during post-market safety evaluations and signal assessments.

What changed: CDA-AMC updated PMDE Program procedures to refine evaluation initiation processes and incorporate real-world data for safety reviews and regulatory decisions.

Why it matters: The update alters how MAHs interact with Canadian authorities during post-market safety evaluations and signal assessments, potentially impacting submission timelines and data requirements.

Practical implication: Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Post-Market Safety#Real-World Evidence#Signal Management#SOP#revised#Canada's Drug Agency (CDA-AMC)#Country Requirement#policy-change

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward